AKT1
AKT1 is a gene that plays a critical role in various cellular processes, including metabolism, cell proliferation, cell survival, growth, and angiogenesis. It is part of the PI3K/AKT/mTOR pathway, a signaling pathway that is vital for cellular growth and survival. This pathway is often dysregulated in various types of cancer, making AKT1 a significant focus of oncology research.
Function[edit | edit source]
AKT1 encodes a serine/threonine protein kinase that is activated by phosphorylation in response to various growth factors and hormones. Once activated, AKT1 phosphorylates a wide range of substrates involved in the regulation of cell survival, cell cycle progression, and apoptosis (programmed cell death). This kinase plays a key role in preventing apoptosis induced by cellular stress or damage, thereby promoting cell survival and growth.
Clinical Significance[edit | edit source]
The AKT1 gene is implicated in several human diseases, most notably in cancer. Mutations and amplifications of AKT1 have been identified in a variety of cancers, including breast cancer, ovarian cancer, and lung cancer. These alterations lead to the hyperactivation of the AKT1 kinase, promoting uncontrolled cell growth and survival, which are hallmarks of cancer. As such, AKT1 is a target for cancer therapy, with several inhibitors being developed to block its activity.
In addition to cancer, AKT1 mutations have been associated with other conditions, such as the Proteus syndrome, a rare disorder characterized by overgrowth of tissues and organs. The precise role of AKT1 in this condition is still under investigation.
AKT1 and Cancer Therapy[edit | edit source]
Given its central role in cell survival and growth, AKT1 is a promising target for cancer therapy. Inhibitors of AKT1 are being developed and tested in clinical trials, with the aim of blocking the aberrant signaling pathway in cancer cells. These inhibitors have the potential to suppress tumor growth and enhance the effectiveness of existing cancer treatments.
See Also[edit | edit source]
 | This oncology article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
